Aralez Pharma (ARLZ): Catalysts Ahead - Guggenheim

August 15, 2016 8:38 AM EDT
Get Alerts ARLZ Hot Sheet
Price: $4.24 -3.64%

Rating Summary:
    1 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 17 | New: 13
Trade ARLZ Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Guggenheim analyst, Louise Chen, reiterated her Buy rating on shares of Aralez Pharmaceuticals (NASDAQ: ARLZ) and commented on upcoming catalysts for the company. The analyst expects approval of Yosprala on its PDUFA date on 9/14. ARLZ has been preparing for the launch by expanding its cardiovascular salesforce and launching promotional efforts for its other cardiovascular drugs. If approved, the company should launch the drug in 4Q16. She estimates peak sales of $200MM by '22, which is not fully reflected in consensus expectations.

For an analyst ratings summary and ratings history on Aralez Pharmaceuticals click here. For more ratings news on Aralez Pharmaceuticals click here.

Shares of Aralez Pharmaceuticals closed at $4.69 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Louise Chen, PDUFA, Guggenheim

Add Your Comment